Relevant bibliographies by topics / Vaccines Effectiveness

Academic literature on the topic 'Vaccines Effectiveness'

Author: Grafiati
Published: 4 June 2021
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Vaccines Effectiveness.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Journal articles on the topic "Vaccines Effectiveness":

1

Trombetta, Claudia Maria, Otfried Kistner, Emanuele Montomoli, Simonetta Viviani, and Serena Marchi. "Influenza Viruses and Vaccines: The Role of Vaccine Effectiveness Studies for Evaluation of the Benefits of Influenza Vaccines." Vaccines 10, no. 5 (May 1, 2022): 714. http://dx.doi.org/10.3390/vaccines10050714.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Influenza is a vaccine preventable disease and vaccination remains the most effective method of controlling the morbidity and mortality of seasonal influenza, especially with respect to risk groups. To date, three types of influenza vaccines have been licensed: inactivated, live-attenuated, and recombinant haemagglutinin vaccines. Effectiveness studies allow an assessment of the positive effects of influenza vaccines in the field. The effectiveness of current influenza is suboptimal, being estimated as 40% to 60% when the vaccines strains are antigenically well-matched with the circulating viruses. This review focuses on influenza viruses and vaccines and the role of vaccine effectiveness studies for evaluating the benefits of influenza vaccines. Overall, influenza vaccines are effective against morbidity and mortality in all age and risk groups, especially in young children and older adults. However, the effectiveness is dependent on several factors such as the age of vaccinees, the match between the strain included in the vaccine composition and the circulating virus, egg-adaptations occurring during the production process, and the subject’s history of previous vaccination.
2

Helena De Oliveira, Lucia, Barbara Jauregui, Ana Flavia Carvalho, and Norberto Giglio. "Impact and effectiveness of meningococcal vaccines: a review." Revista Panamericana de Salud Pública 41 (December 20, 2017): 1. http://dx.doi.org/10.26633/rpsp.2017.158.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Objectives.To summarize and critically evaluate the evidence on the impact and effectiveness of meningococcal vaccination programs around the world in order to inform decisionmaking in Latin America and the Caribbean.Methods.A review of the literature was conducted following several components of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed Central® was searched for papers published in any language from January 1999 – March 2017.Results.In all, 32 studies were included, most of which evaluated the meningococcal C conjugate vaccine. Fourteen studies measured effectiveness and 30 measured impact. The effectiveness of polysaccharide vaccines was 65% – 83.7% (different age groups), while the effectiveness of the conjugate vaccines was 66% – 100%. Incidence decline of laboratory-confirmed meningococcal disease for the conjugate vaccine ranged from 77% – 100% among different ages groups. The only study that evaluated the protein subunit vaccine reported a vaccine effectiveness of 82.9%.Conclusions.The studies reviewed show impact and effectiveness of both polysaccharide vaccines and conjugate vaccines on vaccine-serogroup meningococcal disease. The conjugate vaccines, however, show higher impact and effectiveness with longer-lasting protection over the polysaccharide vaccines. Given the variance in potential use of a meningococcal vaccine, epidemiological surveillance systems should be strengthened to inform national decisions.
3

Pálinkás, Anita, and János Sándor. "Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study." Vaccines 10, no. 7 (June 24, 2022): 1009. http://dx.doi.org/10.3390/vaccines10071009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Our investigation aimed to describe the all-cause mortality rates by COVID-19 vaccination groups in Hungary for an epidemic period (1 April 2021–20 June 2021) and a nonepidemic period (21 June 2021–15 August 2021), and to determine the vaccines’ effectiveness in preventing all-cause mortality utilizing nonepidemic effectiveness measures to adjust for the healthy vaccinee effect (HVE). Sociodemographic status, comorbidity, primary care structural characteristics, and HVE-adjusted survival difference between fully vaccinated and unvaccinated cohorts in the epidemic period had been computed by Cox regression models, separately for each vaccine (six vaccines were available in Hungary). Hazard ratio (HR) reduction in epidemic period corrected with nonepidemic period’s HR with 95% confidence interval for each vaccine was used to describe the vaccine effectiveness (VE). The whole adult population (N = 6,404,702) of the country was followed in this study (4,026,849 fully vaccinated). Each vaccine could reduce the HVE-corrected all-cause mortality in the epidemic period (VEOxford/AstraZeneca = 0.592 [0.518–0.655], VEJanssen = 0.754 [0.628–0.838], VEModerna = 0.573 [0.526–0.615], VEPfizer-BioNTech = 0.487 [0.461–0.513], VESinopharm = 0.530 [0.496–0.561], and VESputnik V = 0.557 [0.493–0.614]). The HVE-corrected general mortality for COVID-19 vaccine cohorts demonstrated the real-life effectiveness of vaccines applied in Hungary, and the usefulness of this indicator to convince vaccine hesitants.
4

Kamolratanakul, Supitcha, and Punnee Pitisuttithum. "Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer." Vaccines 9, no. 12 (November 30, 2021): 1413. http://dx.doi.org/10.3390/vaccines9121413.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Human papillomavirus (HPV) is the most common sexually transmitted infection, with 15 HPV types related to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers. However, cervical cancer remains one of the most common cancers in women, especially in developing countries. Three HPV vaccines have been licensed: bivalent (Cervarix, GSK, Rixensart, Belgium), quadrivalent (Merck, Sharp & Dome (Merck & Co, Whitehouse Station, NJ, USA)), and nonavalent (Merck, Sharp & Dome (Merck & Co, Whitehouse Station, NJ, USA)). The current HPV vaccine recommendations apply to 9 years old and above through the age of 26 years and adults aged 27–45 years who might be at risk of new HPV infection and benefit from vaccination. The primary target population for HPV vaccination recommended by the WHO is girls aged 9–14 years, prior to their becoming sexually active, to undergo a two-dose schedule and girls ≥ 15 years of age, to undergo a three-dose schedule. Safety data for HPV vaccines have indicated that they are safe. The most common adverse side-effect was local symptoms. HPV vaccines are highly immunogenic. The efficacy and effectiveness of vaccines has been remarkably high among young women who were HPV seronegative before vaccination. Vaccine efficacy was lower among women regardless of HPV DNA when vaccinated and among adult women. Comparisons of the efficacy of bivalent, quadrivalent, and nonavalent vaccines against HPV 16/18 showed that they are similar. However, the nonavalent vaccine can provide additional protection against HPV 31/33/45/52/58. In a real-world setting, the notable decrease of HPV 6/11/16/18 among vaccinated women compared with unvaccinated women shows the vaccine to be highly effective. Moreover, the direct effect of the nonavalent vaccine with the cross-protection of bivalent and quadrivalent vaccines results in the reduction of HPV 6/11/16/18/31/33/45/52/58. HPV vaccination has been shown to provide herd protection as well. Two-dose HPV vaccine schedules showed no difference in seroconversion from three-dose schedules. However, the use of a single-dose HPV vaccination schedule remains controversial. For males, the quadrivalent HPV vaccine possibly reduces the incidence of external genital lesions and persistent infection with HPV 6/11/16/18. Evidence regarding the efficacy and risk of HPV vaccination and HIV infection remains limited. HPV vaccination has been shown to be highly effective against oral HPV type 16/18 infection, with a significant percentage of participants developing IgG antibodies in the oral fluid post vaccination. However, the vaccines’ effectiveness in reducing the incidence of and mortality rates from HPV-related head and neck cancers should be observed in the long term. In anal infections and anal intraepithelial neoplasia, the vaccines demonstrate high efficacy. While HPV vaccines are very effective, screening for related cancers, as per guidelines, is still recommended.
5

Izurieta, Hector S., Yoganand Chillarige, Jeffrey Kelman, Yuqin Wei, Yun Lu, Wenjie Xu, Michael Lu, et al. "Relative Effectiveness of Influenza Vaccines Among the United States Elderly, 2018–2019." Journal of Infectious Diseases 222, no. 2 (February 26, 2020): 278–87. http://dx.doi.org/10.1093/infdis/jiaa080.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Abstract Background Studies among individuals ages ≥65 years have found a moderately higher relative vaccine effectiveness (RVE) for the high-dose (HD) influenza vaccine compared with standard-dose (SD) products for most seasons. Studies during the A(H3N2)-dominated 2017–2018 season showed slightly higher RVE for the cell-cultured vaccine compared with SD egg-based vaccines. We investigated the RVE of influenza vaccines among Medicare beneficiaries ages ≥65 years during the 2018–2019 season. Methods This is a retrospective cohort study using inverse probability of treatment weighting and Poisson regression to evaluate RVE in preventing influenza hospital encounters. Results Among 12 777 214 beneficiaries, the egg-based adjuvanted (RVE, 7.7%; 95% confidence interval [CI], 3.9%–11.4%) and HD (RVE, 4.9%; 95% CI, 1.7%–8.1%) vaccines were marginally more effective than the egg-based quadrivalent vaccines. The cell-cultured quadrivalent vaccine was not significantly more effective than the egg-based quadrivalent vaccine (RVE, 2.5%; 95% CI, −2.4% to 7.3%). Conclusions We did not find major effectiveness differences between licensed vaccines used among the elderly during the 2018–2019 season. Consistent with prior research, we found that the egg-based adjuvanted and HD vaccines were slightly more effective than the egg-based quadrivalent vaccines.
6

Diogo José Horst and Charles Adriano Duvoisin. "The doubtful effectiveness of the COVID-19 vaccine." GSC Biological and Pharmaceutical Sciences 15, no. 2 (May 30, 2021): 151–57. http://dx.doi.org/10.30574/gscbps.2021.15.2.0132.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
A COVID-19 pandemic has erupted around the world. World Health Organization (WHO) and allies are racing to create and deploy safe and effective vaccines as they work together to monitor the pandemic, advise on crucial measures, and distribute essential medical resources to those in need. Vaccines save millions of lives, by training the body's natural defenses, the immune system, to identify and combat the viruses and bacteria they are intended to combat. This review article presents the status of COVID-19 vaccines evaluated by the WHO Emergency Use Listing (EUL) assessment process and those liberated as well. Data was obtained from the WHO, Gavi – The Vaccine Alliance from Bill & Melinda Gates Foundation, Oxford Vaccine Group, Serum Institute of India, AstraZeneca, European Medicines Agency EMA among others. As can be seen, there is still no totally effective vaccine, and many clinical trials are still needed, and even immunized citizens are still at risk of recontagion. Virus mutation is a recurring problem and different vaccine production methodologies are still being studied.
7

Knight-Jones, T. J. D., K. Edmond, S. Gubbins, and D. J. Paton. "Veterinary and human vaccine evaluation methods." Proceedings of the Royal Society B: Biological Sciences 281, no. 1784 (June 7, 2014): 20132839. http://dx.doi.org/10.1098/rspb.2013.2839.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Despite the universal importance of vaccines, approaches to human and veterinary vaccine evaluation differ markedly. For human vaccines, vaccine efficacy is the proportion of vaccinated individuals protected by the vaccine against a defined outcome under ideal conditions, whereas for veterinary vaccines the term is used for a range of measures of vaccine protection. The evaluation of vaccine effectiveness , vaccine protection assessed under routine programme conditions, is largely limited to human vaccines. Challenge studies under controlled conditions and sero-conversion studies are widely used when evaluating veterinary vaccines, whereas human vaccines are generally evaluated in terms of protection against natural challenge assessed in trials or post-marketing observational studies. Although challenge studies provide a standardized platform on which to compare different vaccines, they do not capture the variation that occurs under field conditions. Field studies of vaccine effectiveness are needed to assess the performance of a vaccination programme. However, if vaccination is performed without central co-ordination, as is often the case for veterinary vaccines, evaluation will be limited. This paper reviews approaches to veterinary vaccine evaluation in comparison to evaluation methods used for human vaccines. Foot-and-mouth disease has been used to illustrate the veterinary approach. Recommendations are made for standardization of terminology and for rigorous evaluation of veterinary vaccines.
8

Stöckli, Sabrina, Anna Katharina Spälti, Joseph Phillips, Florian Stoeckel, Matthew Barnfield, Jack Thompson, Benjamin Lyons, Vittorio Mérola, Paula Szewach, and Jason Reifler. "Which vaccine attributes foster vaccine uptake? A cross-country conjoint experiment." PLOS ONE 17, no. 5 (May 4, 2022): e0266003. http://dx.doi.org/10.1371/journal.pone.0266003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Why do people prefer one particular COVID-19 vaccine over another? We conducted a pre-registered conjoint experiment (n = 5,432) in France, Germany, and Sweden in which respondents rated the favorability of and chose between pairs of hypothetical COVID-19 vaccines. Differences in effectiveness and the prevalence of side-effects had the largest effects on vaccine preferences. Factors with smaller effects include country of origin (respondents are less favorable to vaccines of Chinese and Russian origin), and vaccine technology (respondents exhibited a small preference for hypothetical mRNA vaccines). The general public also exhibits sensitivity to additional factors (e.g. how expensive the vaccines are). Our data show that vaccine attributes are more important for vaccine preferences among those with higher vaccine favorability and higher risk tolerance. In our conjoint design, vaccine attributes–including effectiveness and side-effect prevalence–appear to have more muted effects among the most vaccine hesitant respondents. The prevalence of side-effects, effectiveness, country of origin and vaccine technology (e.g., mRNA vaccines) determine vaccine acceptance, but they matter little among the vaccine hesitant. Vaccine hesitant people do not find a vaccine more attractive even if it has the most favorable attributes. While the communication of vaccine attributes is important, it is unlikely to convince those who are most vaccine hesitant to get vaccinated.
9

Erofeeva, M. K., M. A. Stukova, E. V. Shakhlanskaya, Zh V. Buzitskaya, V. L. Maksakova, T. I. Krainova, M. M. Pisareva, A. B. Popov, M. G. Pozdnjakova, and D. A. Lioznov. "Evaluation of the Preventive Effectiveness of Influenza Vaccines in the Epidemic Season 2019–2020 in St. Petersburg." Epidemiology and Vaccinal Prevention 20, no. 5 (November 5, 2021): 52–60. http://dx.doi.org/10.31631/2073-3046-2021-20-5-52-60-52-60.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Background. The vaccine is the best available instrument to prevent influenza and reduce the risks of major disease complications and mortality. The vaccine effectiveness during the influenza season depends on a number of factors: (1) a person vaccinated (their age and health status); (2) the vaccine formulation; (3) types and subtypes of the circulating viruses; (4) vaccination timeline, as the immune response fades over time. An influenza vaccine can yield different effectiveness in people who have been infected or vaccinated previously and in those who have not been yet exposed to the circulating viruses. At present, trivalent and quadrivalent influenza vaccines are registered and produced in Russia. It allows for vaccination of all social groups, including high-risk populations, and for increasing the number of vaccinated individuals yearly. Russian Federation constantly improves the production of influenza vaccines, introducing new variants of vaccine formulations into national clinical usage. It is thus essential to monitor and analyze the changes in the effectiveness of influenza vaccines every season.Aim of the study. To evaluate of the effectiveness of Russian domestic influenza vaccines during the epidemic season 2019–2020 in St. Petersburg compared to the season 2018–2019.Materials and Methods. 3315 female and male adult participants aged 18 years and older were monitored from October 2019 to March 2020. The group included university students and tutors, researchers, and production and office workers of industrial enterprises. Sovigripp, Grippol Plus, Ultrix, and Ultrix Quadri influenza vaccines were used for immunization.Results and Discussion. In the context of incomplete correspondence between the viruses circulating in Russia and the strains used in the vaccines, the vaccination of the St. Petersburg population during the epidemic season 2019-2020 with Sovigripp, Grippol Plus, Ultrix, and Ultrix Quadri influenza vaccines cumulatively reduced influenza and ARI incidences by half; the total vaccine effectiveness against influenza and ARI amounted to 50.0%. The strongest preventive effect was identified for Grippol Plus, Ultrix, and Ultrix Quadri which demonstrated the total vaccine effectiveness from 70.6% to 75.0%, and their effectiveness against influenza A and B viruses reached from 65.5% to 83.5%.Conclusion. In the context of incomplete correspondence between the viral strains used in the vaccines and the strains circulating in Russia and St. Petersburg during the epidemic season 2019- 2020 and considering the active circulation of non-influenza viruses such as rhinoviruses and adenoviruses, we found a moderate preventive effectiveness of the influenza vaccines during the seasonal epidemic increase in ARI cases. Russian domestic influenza vaccines were shown to have good acceptability, be safe, and non-reactogenic.
10

Rajaram, Sankarasubramanian, Constantina Boikos, Daniele K. Gelone, and Ashesh Gandhi. "Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing." Therapeutic Advances in Vaccines and Immunotherapy 8 (January 2020): 251513552090812. http://dx.doi.org/10.1177/2515135520908121.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Influenza continues to cause severe illness in millions and deaths in hundreds of thousands annually. Vaccines are used to prevent influenza outbreaks, however, the influenza virus mutates and annual vaccination is required for optimal protection. Vaccine effectiveness is also affected by other potential factors such as the human immune system, a mismatch with the chosen candidate virus, and egg adaptation associated with egg-based vaccine production. This article reviews the influenza vaccine development process and describes the implications of the changes to the cell-culture process and vaccine strain recommendations by the World Health Organization since the 2017 season. The traditional manufacturing process for influenza vaccines relies on fertilized chicken eggs that are used for vaccine production. Vaccines must be produced in large volumes and the complete process requires approximately 6 months for the egg-based process. In addition, egg adaptation of seed viruses occurs when viruses adapt to avian receptors found within eggs to allow for growth in eggs. These changes to key viral antigens may result in antigenic mismatch and thereby reduce vaccine effectiveness. By contrast, cell-derived seed viruses do not require fertilized eggs and eliminate the potential for egg-adapted changes. As a result, cell-culture technology improves the match between the vaccine virus strain and the vaccine selected strain, and has been associated with increased vaccine effectiveness during a predominantly H3N2 season. During the 2017–2018 influenza season, a small number of studies conducted in the United States compared the effectiveness of egg-based and cell-culture vaccines and are described here. These observational and retrospective studies demonstrate that inactivated cell-culture vaccines were more effective than egg-based vaccines. Adoption of cell-culture technology for influenza vaccine manufacturing has been reported to improve manufacturing efficiency and the additional benefit of improving vaccine effectiveness is a key factor for future policy making considerations.
More sources
You might also be interested in the extended bibliographies on the topic 'Vaccines Effectiveness' for particular source types:
Journal articles Dissertations / Theses

Dissertations / Theses on the topic "Vaccines Effectiveness":

1

Ming, Wai-kit, and 明偉傑. "Effectiveness of universal rotavirus vaccination: a literature review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B50222995.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Objectives This study focuses on the evaluation of the use of vaccine in the prevention of severe acute gastroenteritis in the community in the literature. The objectives of this project report include an in depth review of the effectiveness and cost effectiveness of rotavirus vaccination for severe acute gastroenteritis in low and middle income countries (developing countries). Methods Publications were identified using computerized bibliographic searches in PubMed (for the period from October 1994 to July 2012). The keywords “effective*”, “vaccin*”, “rotavirus” , “Randomized controlled trial” were used to search for relevant information. Also the keywords “轮状病毒”, “疫苗” , “随机对照试验” were used to search for relevant information in China Journals Full-text Database(中国期刊全文数据库). Selection criteria: SSRandomized controlled trials (RCT) in children (<5 years old) comparing rotavirus RV1/RV5/LLR vaccines for use with (1) placebo, (2) no intervention, or (3) another RV1/RV5/LLR vaccine. Once the identified articles had been screened by the inclusion and exclusion criteria, the content of each was evaluated in relation to the two research questions. International guidelines: CONSORT (for RCT) was also followed in the quality assessment process. Results In our review, there were 9 studies included and 2 of them were graded A(i.e. good quality), 5 graded B(i.e. medium quality) and 2 graded C(i.e. poor quality). For the two Grade A studies, vaccine effectiveness was estimated to be 39.3% and 48.3%. For 5 Grade B studies, vaccine effectiveness was estimated to be 19.2% to 63.9%. For 2 Grade C studies, vaccine effectiveness was estimated to be 10.6% and 74.3%. There is a smaller range in vaccine effectiveness in grade A studies. In contrast, there is a greater range in vaccine effectiveness in grade B and C studies. Many low and middle income countries may not have enough training in conducting RCT. However, the Grade A studies showed that rotavirus vaccine is effective. Our review also showed that authors from most of the low income countries suggested that rotavirus vaccine is cost effective to very cost effective, while those from middle income countries suggested that the cost of the vaccine is the key factor. Conclusion This review showed evidence of effectiveness of rotavirus vaccine and cost-effectiveness in low and middle income countries (developing countries). China has a huge population and similar situation with other developing countries, hence it is useful to conduct a study on cost-effectiveness on universal vaccination in the near future.
published_or_final_version
Public Health
Master
Master of Public Health
2

Boros, Christina Ann. "Factors affecting the immunogenicity and protective efficacy of routine childhood immunisations." Title page, contents and abstract only, 2001. http://web4.library.adelaide.edu.au/theses/09PH/09phb736.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Includes list of publications arising from the thesis. Bibliography: leaves 327-341. Examines the effect of adverse storage on the immunogenicity of pertussis, diphtheria and tetanus vaccines, the protective efficacy of pertussis vaccines and the effect of premature birth on antibody response to routine childhood immunisations.
3

Yuen, Wing-mei, and 阮泳薇. "Systematic review on the cost effectiveness of human papillomavirus vaccination in Asia and its implication in Hong Kong." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48427329.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Background: Human papillomavirus vaccination is newly developed in this decade. There are 2 types of vaccines. Bivalent vaccine targets on HPV types 16, 18 to prevent cervical cancer. Quadrivalent vaccine target on HPV type 6, 11, 16, 18 to prevent genital warts and cervical cancer. England has adopted a population –based HPV vaccination program. In attempt to find out the worthiness to implement the population-based vaccination program in Hong Kong, this project reviewed 15 cost-effectiveness analyses in Asian countries. Asian countries may have the similar characteristics, such as culture, sex behavior, genome, etc, that makes the result more applicable to Hong Kong. Methodology: Cost-effectiveness analysises of human papillomavirus vaccination were identified by the searching engine MEDLINE (Ovid) by using relevant keywords. All English and Chinese articles relevant to the topic were identified. Articles conducted for the cost-effectiveness of human papillomavirus vaccine in Asian countries were considered as the potential literature for the review. Result and Discussion: The searching engine identified 259 literatures, 16 of them are in Asian countries, 1 of them did not meet the criteria of quality assessment. 15 of them are included in this review. 6 different model approaches were used in the 15 articles. Results from the same countries in 2 separated articles were heterogeneous. That may probably due to the different assumption and perspectives used. Different perspectives would include different costing. Studies only including the direct cost would likely over-estimate the cost-effectiveness of the vaccine. The threshold value adopted would also affect the result. A stricter threshold value would under-estimate the cost-effectiveness. Some low-and-middle income countries has no available data on the vaccination because the vaccine is not available in the market, the data would only rely on the past literature or international data. 12 out of the 15 studies showed that the vaccination is cost-effective in the countries. Conclusion and Implication: the ICER is sensitive to the price of the vaccine, the efficacy, the duration of protection, the discount rate, the screening coverage rate, and the age of receiving vaccination, the vaccination coverage rate and the cervical cancer or genital warts incidence rate. Some studies showed that regular screening combined with vaccination program would be cost-effective. In the studies comparing the 2 types of vaccines, all the results showed that quadrivalent vaccine dominant to the bivalent vaccine. Moreover, the vaccination would decrease the cervical cancer incidence by 20% to 90%. In view of the prevalence of HPV type and the high incidence rate of genital warts. The quadrivalent vaccine is likely beneficial to Hong Kong
published_or_final_version
Public Health
Master
Master of Public Health
4

Cheung, Ka-mei Camy, and 張嘉楣. "The cost-effectiveness of human pappillomavirus vaccines in men : a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/193771.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Background Human Papillomavirus (HPV) infection is the most common sexually transmitted infection worldwide. It is the leading cause of genital warts and cervical cancer, and is strongly associated with oropharyngeal and other anogenital cancers. To date, two prophylactic HPV vaccines are available, both of which have shown high efficacies in protection against vaccine-type HPV infection and HPV-associated diseases in both males and females. Despite the proven efficacies, male vaccination has not been included in any national vaccination programme worldwide. In Hong Kong, vaccine uptake remains low despite the Department of Health’s recommendation, and a routine comprehensive vaccination programme is yet to be adopted. However, very limited cost-effectiveness data are available to guide policy makers on the economic potential of implementing routine HPV vaccination, especially that of extending vaccination to males. This systematic review is among the first to evaluate the latest cost-effectiveness analyses of HPV vaccination in men and apply the synthesis to the context of Hong Kong, which will help local policy makers in their consideration of implementing a comprehensive HPV vaccination programme in Hong Kong, especially whether to extend vaccination to males. Methodology A systematic review was conducted to retrieve literatures that provide full economic evaluations of cost-effectiveness analyses of HPV vaccination programmes that included males, by searching in the MEDLINE (Ovid system) using relevant keywords. English articles that provide full economic evaluations of cost-effectiveness analyses of HPV vaccination programmes in men or in both sexes in the age group of 9-45 years were considered as potential studies for inclusion in this review. Results The literature search identified 117 studies, 107 among them failed to meet the inclusion criteria, 2 were duplicated studies, 1 did not meet the quality assessment criteria described by Drummond et al. A total of 7 studies were included in this review. All studies adopted dynamic models, except one using static model, which did not take into account the effect of herd immunity on HPV transmission. The studies measured the cost-effectiveness using different assumptions on vaccine costs, coverage, efficacies, duration of protection, costing and perspectives. Only several studies took a societal perspective in their analyses and included non-medical and indirect costs. 4 among all studies explored the cost-effectiveness of extending HPV vaccination to males, 2 only focused on female-only HPV vaccination with indirect benefits to males, and 1 only evaluated vaccination of the men who have sex with men (MSM) population. The discrepancies in different costing and outcome measures lowered the comparability of cost-effectiveness analyses. Yet, in general, the studies reported vaccine efficacies and duration of protection to significantly impact the cost-effectiveness of vaccination in both sexes. Moreover, vaccine coverage is critical to influence cost-effectiveness, for male vaccination would only be cost-effective given a female vaccine coverage of 50% or below. Conclusion and Implications Evidence from recent cost-effectiveness analyses suggested that vaccinating 12-year-olds is cost-effective. School-based immunization programmes are recommended to vaccinate the population at an early age before sexual debut for better clinical and economic benefits. Extending HPV vaccination to boys will be cost-effective when female vaccine coverage is low. Given a low vaccine uptake rate among schoolgirls in Hong Kong, policy makers should consider expanding vaccination to boys when implementing a routine immunization programme by synthesizing findings from epidemiological and economic evaluations.
published_or_final_version
Community Medicine
Master
Master of Public Health
5

Lau, Tin-wai. "Effectiveness of influenza vaccine among elderly people living in residential care homes during outbreak situations." Click to view the E-thesis via HKUTO, 2005. http://sunzi.lib.hku.hk/hkuto/record/b39724177.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mezones, Holguín Edward, Díaz Rafael Bolaños, Víctor Fiestas, César Sanabria, Aguado Alfonso Gutiérrez, Fabián Fiestas, Víctor J. Suárez, Morales Alfonso J. Rodríguez, and Adrian V. Hernández. "Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children." The Journal of Infection in Developing Countries, 2015. http://hdl.handle.net/10757/337985.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
emezones@gmail.com
Introduction: Pneumococcal pneumonia (PP) has a high burden of morbimortality in children. Use of pneumococcal conjugate vaccines (PCVs) is an effective preventive measure. After PCV 7-valent (PCV7) withdrawal, PCV 10-valent (PCV10) and PCV 13-valent (PCV13) are the alternatives in Peru. This study aimed to evaluate cost effectiveness of these vaccines in preventing PP in Peruvian children <5 yearsold. Methodology: A cost-effectiveness analysis was developed in three phases: a systematic evidence search for calculating effectiveness; a cost analysis for vaccine strategies and outcome management; and an economic model based on decision tree analysis, including deterministic and probabilistic sensitivity analysis using acceptability curves, tornado diagram, and Monte Carlo simulation. A hypothetic 100 vaccinated children/vaccine cohort was built. An incremental cost-effectiveness ratio (ICER) was calculated. Results: The isolation probability for all serotypes in each vaccine was estimated: 38% for PCV7, 41% PCV10, and 17% PCV13. Avoided hospitalization was found to be the best effectiveness model measure. Estimated costs for PCV7, PCV10, and PCV13 cohorts were USD13,761, 11,895, and 12,499, respectively. Costs per avoided hospitalization were USD718 for PCV7, USD333 for PCV10, andUSD 162 for PCV13. At ICER, PCV7 was dominated by the other PCVs. Eliminating PCV7, PCV13 was more cost effective than PCV10 (confirmed in sensitivity analysis). Conclusions: PCV10 and PCV13 are more cost effective than PCV7 in prevention of pneumonia in children <5 years-old in Peru. PCV13 prevents more hospitalizations and is more cost-effective than PCV10. These results should be considered when making decisions about the Peruvian National Inmunizations Schedule.
This study was funded by Instituto Nacional de Salud, Lima, Peru
Revisión pór pares
7

Mezones, Holguín Edward, Aybara Carlos Canelo, Clark Andrew David, Janusz Cara Bess, Bárbara Jaúregui, Palza Seimer Escobedo, Adrian V. Hernandez, et al. "Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru." Elsevier B.V, 2015. http://hdl.handle.net/10757/582635.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Objective To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine (PCV10) versus the 13-valent PCV (PCV13) to the National Immunization Schedule in Peru for prevention of pneumococcal disease (PD) in children <5 years of age. Methods The integrated TRIVAC vaccine cost-effectiveness model from the Pan American Health Organization's ProVac Initiative (version 2.0) was applied from the perspective of the Government of Peru. Twenty successive cohorts of children from birth to 5 years were evaluated. Clinical outcomes were pneumococcal pneumonia (PP), pneumococcal meningitis (PM), pneumococcal sepsis (PS) and acute otitis media from any causes (AOM). Measures included prevention of cases, neurological sequelae (NS), auditory sequelae (AS), deaths and disability adjusted life years (DALYs). A sensitivity analyses was also performed. Findings For the 20 cohorts, net costs with PCV10 and PCV13 were US$ 363.26 million and US$ 408.26 million, respectively. PCV10 prevented 570,273 AOM; 79,937 PP; 2217 PM; 3049 PS; 282 NS; 173 AS; and 7512 deaths. PCV13 prevented 419,815 AOM; 112,331 PN; 3116 PM; 4285 PS; 404 NS; 248 AS; and 10,386 deaths. Avoided DALYs were 226,370 with PCV10 and 313,119 with PCV13. Saved treatment costs were US$ 37.39 million with PCV10 and US$ 47.22 million with PCV13. Costs per DALY averted were US$ 1605 for PCV10, and US$ 1304 for PCV13. Sensitivity analyses showed similar results. PCV13 has an extended dominance over PCV10. Conclusion Both pneumococcal vaccines are cost effective in the Peruvian context. Although the net cost of vaccination with PCV10 is lower, PCV13 prevented more deaths, pneumococcal complications and sequelae. Costs per each prevented DALY were lower with PCV13. Thus, PCV13 would be the preferred policy; PCV10 would also be reasonable (and cost-saving relative to the status quo) if for some reason 13-valent were not feasible.
This study was presented at 9th International Symposium of Pneumococci and Pneumococcal Diseases, Hyderabad, India, March 2014, and supported by the National Council of Science, Technology and Technological Innovation of Peru (CONCYTEC) and International Clinical Epidemiology Network (INCLEN Trust)
This study was made possible through the financial support of the Instituto Nacional de Salud (National Institute of Health, Lima, Peru) and the PROVAC Initiative of the Pan American Health Organization (Washington, DC, USA).
8

Marlow, Robin. "Assessing the impact and cost-effectiveness of rotavirus vaccines in the United Kingdom." Thesis, University of Bristol, 2016. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.705468.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sharma, Aditya. "Cost-effectiveness of Hepatitis A and Hepatitis B Vaccination for Jail Inmates." Yale University, 2008. http://ymtdl.med.yale.edu/theses/available/etd-08272007-114829/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Despite evidence that viral hepatitis poses a significant risk to public health, universal vaccination has not yet been implemented. The risk for viral hepatitis infection is particularly high among injection drug users and other individuals who do not attend regular health care visits. Jails provide a structural opportunity to vaccinate these high risk individuals. HAV and HBV vaccines administered on an accelerated three week schedule could dramatically decrease the lifetime risk for contracting viral hepatitis among jail detainees. Assuming that 75% of detainees would accept vaccination, 33% have previous exposure to HAV, 25% have previous exposure to HBV, and independent future healthcare costs were US $317,000, the US health care system would save $12 per individual with a vaccinate upon entry program in comparison to no intervention. This savings translates into an economic benefit amounting to about US$ 5,000,000 saved if all new jail inmates in a given year were immunized. A vaccination upon entry program for HAV/HBV in jails should be widely implemented with coordination between the corrections system and public health agencies to reduce the growing cost of viral hepatitis infection.
10

Koh, Naoko. "Cost-benefit analysis of influenza vaccination for children in Hong Kong." Thesis, Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/hkuto/record/B31971866.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Vaccines Effectiveness":

1

Sullivan, Louis Wade. Cost-effectiveness demonstration of Medicare coverage of influenza vaccine: Report to Congress. [Washington, D.C.?: Dept. of Health and Human Services], 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shalala, Donna E. Medicare influenza vaccine demonstration: Report to Congress. [Washington, D.C.?: Dept. of Health and Human Services], 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chan, Kwai-Cheung. Medical readiness: Issues concerning the anthrax vaccine : statement of Kwai-Cheung Chan, Director, Special Studies and Evaluations, National Security and International Affairs Division, before the Subcommittee on National Security, Veterans' Affairs, and International Relations, Committee on Government Reform, House of Representatives. Washington, D.C. (P.O. Box 37050, Washington, D.C. 20013): The Office, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chan, Kwai-Cheung. Medical readiness: Safety and efficacy of the anthrax vaccine : statement of Kwai-Cheung Chan, Director, Special Studies and Evaluations, National Security and International Affairs Division, before the Subcommittee on National Security, Veterans' Affairs, and International Relations, Committee on Government Reform, House of Representatives. Washington, D.C: The Office, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chan, Kwai-Cheung. Medical readiness: Safety and efficacy of the anthrax vaccine : statement of Kwai-Cheung Chan, Director, Special Studies and Evaluations, National Security and International Affairs Division, before the Subcommittee on National Security, Veterans' Affairs, and International Relations, Committee on Government Reform, House of Representatives. Washington, D.C: The Office, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Taehak, Sŏul Taehakkyo Ŭikwa, ed. Inpʻŭlluenja paeksin (soa) yuyongsŏng pʻyŏngka yŏnʼgu: Yŏnʼgu kyŏlgwa pogosŏ = Evaluation of efficacy of influenza vaccine in children. [Seoul]: Sikpʻum Ŭiyakpʻum Anjŏnchʻŏng, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Communicating about Vaccine Safety: Guidelines to help health workers communicate with parents, caregivers, and patients. Pan American Health Organization, 2021. http://dx.doi.org/10.37774/9789275122822.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Vaccines save between 2 million and 3 million lives each year and protect the entire population from more than a dozen life-threatening diseases. Thanks to vaccination, smallpox was eradicated in 1980, and we are on track to eradicate polio. However, despite great strides in the control of measles, one of the most contagious diseases known, the last few years have unfortunately seen an increase in cases. This is why high vaccination coverage—95% or more—is needed, posing a major technical and communication challenge for health workers. Studies show that telling people about the quality, safety, effectiveness and availability of vaccines is not enough to influence behavior change related to immunization, and in general, doesn´t increase coverage. For this reason, it´s necessary to understand the reasons why people choose not to get vaccinated or not get their children vaccinated, in order to begin a two-way respectful dialogue using the best, most effective messages. Given this context, the main objective of these guidelines is to provide tools for staff working in the field of immunization to support effective communication between health personnel and the general population, with the aim of strengthening, maintaining or recovering trust in vaccines and the immunization programs in the Region of the Americas.
8

Barker, Richard. Lessons from the last 20 years. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198737780.003.0004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
A review of a dozen case examples of pharmaceutical innovation—from HIV to stomach ulcers—and others from vaccines, diagnostics, and medical devices give many pointers to the way forward to more productive and sustainable medical innovation. A sense of urgency, strong patient and public engagement, regulatory flexibility, cross-sector collaboration, and creativity on payment mechanisms all need to be built need to our new models, as we move into an era of precision medicine. We can also learn from other industries—from aerospace to IT—greater innovation around increased cost-effectiveness.
9

Rouse, Carolyn. Evidence of What? Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780190465285.003.0010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
This chapter interrogates an important vogue in the field of African development. Evidence-based approaches to health care, which are being used increasingly, fail to take into account social and cultural factors affecting individuals' health. Bed nets and vaccines are helpful in reducing malaria-related mortality rates in African countries, but nature and culture are indivisible in health and wellness. Malaria and sickle cell anemia are most commonly analyzed using evidence-based approaches, like many medical issues, although there are numerous social factors to be taken into account in their spread among African populations as well as methods of prevention and treatment. Comparative effectiveness research is thus an upgrade from evidence-based research that can be applied to examine the relationship between health and race and behavior.
10

R, Berndt Ernst, and National Bureau of Economic Research., eds. Advanced purchase commitments for a malaria vaccine: Estimating costs and effectiveness. Cambridge, MA: National Bureau of Economic Research, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Vaccines Effectiveness":

1

Myers, Evan R. "Cost-Effectiveness of HPV Vaccines." In Emerging Issues on HPV Infections, 235–41. Basel: KARGER, 2006. http://dx.doi.org/10.1159/000092759.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Whitney, Cynthia G., and Matthew R. Moore. "Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice." In Pneumococcal Vaccines, 351–68. Washington, DC, USA: ASM Press, 2014. http://dx.doi.org/10.1128/9781555815820.ch24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Biggers, John D. "The Potential Effectiveness and Safety of Second Generation Vaccines." In Immunological Approaches to Contraception and Promotion of Fertility, 203–7. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-5140-5_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lehtinen, Matti, Pekka Nieminen, Dan Apter, Proscowa Namujju, Kari Natunen, Mohsin Rana, and Jorma Paavonen. "Immunogenicity, Efficacy, Effectiveness and Overall Impact of HPV Vaccines." In HPV and Cervical Cancer, 257–72. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-1988-4_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bora, Ajitabh, Hemanta Kumar Gogoi, and Vijay Veer. "Molecular Farming for Production of Biopharmaceuticals and Edible Vaccines in Plants." In Herbal Insecticides, Repellents and Biomedicines: Effectiveness and Commercialization, 205–16. New Delhi: Springer India, 2016. http://dx.doi.org/10.1007/978-81-322-2704-5_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mueller, Siguna. "The Challenge of Evaluating Vaccine Safety and Effectiveness." In Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2, 131–62. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-18903-6_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hahné, Susan, Kaatje Bollaerts, and Paddy Farrington. "Vaccine effectiveness." In Vaccination Programmes, 223–44. London: Routledge, 2021. http://dx.doi.org/10.4324/9781315166414-16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nauta, Jozef. "Vaccine Effectiveness Studies." In Springer Series in Pharmaceutical Statistics, 129–50. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-37693-2_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hahné, Susan, Kaatje Bollaerts, and Paddy Farrington. "Estimating vaccine effectiveness." In Vaccination Programmes, 289–308. London: Routledge, 2021. http://dx.doi.org/10.4324/9781315166414-19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hahné, Susan, Kaatje Bollaerts, and Paddy Farrington. "Estimating vaccine effectiveness." In Vaccination Programmes, 245–63. London: Routledge, 2021. http://dx.doi.org/10.4324/9781315166414-17.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Vaccines Effectiveness":

1

Zughaier, Susu. "High Vaccine Coverage is Crucial for Preventing the Spread of Infectious Diseases During Mass Gathering." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0138.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Background: Vaccines are the most cost-effective intervention in public health as they prevent the spread of highly contagious infectious diseases. Because of vaccine implementation and high coverage, Measles was eradicated in 2000, however the recent reappearance of measles in the United States, Europe and globally is alarming. The resurgence of Measles, Diphtheria and Mumps is due to a reduction in vaccine coverage and herd immunity. Vaccine hesitant parents, antivaxxers, and fake news on vaccines are driving the surge in those infectious diseases. The World Health Organization issued the Global Vaccine and Immunization Action Plan to reiterate the importance of vaccine implementation and coverage for several vaccine-preventable infectious diseases in the world. Qatar is preparing for the upcoming FIFA World Cup 2022 therefore maintaining high vaccine coverage, which is critical in preventing infectious diseases spreading during such mass gathering. Methods: Literature search for vaccine coverage rates, resurgence of vaccine preventable infectious diseases and risks of mass gatherings. Results: Seventeen infectious diseases are currently vaccine-preventable. The cost-effectiveness of vaccine is documented as it is estimated for each dollar spent on vaccines, 10 dollars are saved in disease treatment. A drop in vaccine coverage rates to under 90% lead to the resurgence of measles. Vaccine coverage rate in Qatar is currently at 95% which is one of the highest in the world. Qatar must maintain this high coverage rate to prevent any measles outbreaks during mass gatherings. The planned World Cup event will take place from November 21 till December 18 2022, which is the peak for seasonal influenza. In preparedness for this major event, Qatar should encourage residents and visitors to be vaccinated not just against measles and seasonal influenza, but also hepatitis and meningitis. Conclusion: Maintaining 95% vaccine coverage rate is critical for preventing the resurgence of vaccine-preventable infectious diseases during the World Cup mass gathering in Qatar.
2

"Emergence of SARS-CoV-2 Variant of Concern Omicron: Biological Features and Genomic Concern." In International Conference on Public Health and Humanitarian Action. International Federation of Medical Students' Associations - Jordan, 2022. http://dx.doi.org/10.56950/itrx2370.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Abstract Corona virus infection is a worldwide health threat that has infected a substantial portion of the world's population and is caused by SARS-CoV-2. It is the natural tendency of a virus to change the genetic makeup through the point mutation, and such viruses are called the variant of the original virus. SARS-CoV-2 virus also undergoes such mutation (may be one or more and distinct from other) over time, and many genetically diverse variant has risen. Such variants might be of variants of concern (VOC) and variant of interest (VOI) based on the differences in virulence, transmissibility, pathogenicity, and vaccination efficacy. Omicron, a new VOC of SARS-CoV-2, has recently emerged as a global distress to more than 115 countries. The article provides a summary of the evolutionary, biological, and genomic aspects of different SARS-CoV-2 VOC with respect to Omicron and found that amino acid mutation in spike proteins such as A67V, Δ69-70, Q954H, N969K, L981F etc and other structural protein mutations such as D3G, Q19E, A63T in membrane protein, T9I in envelope protein and P13L, Δ31-33, R203K, G204R in nucleocapsid protein results major differences between different VOC/VOI of SARS-CoV-2. Further, effectiveness of the widely used SARS-CoV-2 vaccines has been reviewed specific to Omicron. The existing available COVID-19 vaccines developed and manufactured by Pfizer, AstraZeneca, Johnson & Johnson, Moderna, and Novavax show reduced efficacy against the latest VOC of SARS- CoV-2 Omicron. Based on the available literature of preliminary findings, people who get a booster shot or a third vaccine dosage may have better protected against Omicron. Keywords: SARS-CoV-2, Omicron, Variants of Concern, Variants of Interest, Mutation, Vaccine.
3

Ditamy, Aldila, Beatrice Sasmita, Bella Edytha Kurniawan, I. Putu Indra Widia Kumara, Nathanael Victorius, Shreyasi Sarkar, and Bagus Mulyawan. "The Effectiveness, Side Effects, and Implementation Between Variation of COVID-19 Vaccines in Indonesia." In 3rd Tarumanagara International Conference on the Applications of Social Sciences and Humanities (TICASH 2021). Paris, France: Atlantis Press, 2022. http://dx.doi.org/10.2991/assehr.k.220404.303.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ignatova, G., V. Antonov, and E. Blinova. "Effectiveness of Joint or Sequential Vaccination of Pneumococcal and Flu Vaccines in Chronic Obstructive Pulmonary Disease Patients." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3317.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Xiao, Yichen, Han-Ching Ou, Haipeng Chen, Van Thieu Nguyen, and Long Tran-Thanh. "Sequential Vaccine Allocation with Delayed Feedback." In Thirty-First International Joint Conference on Artificial Intelligence {IJCAI-22}. California: International Joint Conferences on Artificial Intelligence Organization, 2022. http://dx.doi.org/10.24963/ijcai.2022/722.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
In this work we consider the problem of how to best allocate a limited supply of vaccines in the aftermath of an infectious disease outbreak by viewing the problem as a sequential game between a learner and an environment (specifically, a bandit problem). The difficulty of this problem lies in the fact that the payoff of vaccination cannot be directly observed, making it difficult to compare the relative effectiveness of vaccination on different population groups. Currently used vaccination policies make recommendations based on mathematical modelling and ethical considerations. These policies are static, and do not adapt as conditions change. Our aim is to design and evaluate an algorithm which can make use of routine surveillance data to dynamically adjust its recommendation. We evaluate the performance of our approach by applying it to a simulated epidemic of a disease based on real-world COVID-19 data, and show that our vaccination policy was able to perform better than existing vaccine allocation policies. In particular, we show that with our allocation method, we can reduce the number of required vaccination by at least 50% in order to keep the peak number of hospitalised patients below a certain threshold. Also, when the same batch sizes are used, our method can reduce the peak number of hospitalisation by up to 20%. We also demonstrate that our vaccine allocation does not vary the number of batches per group much, making it socially more acceptable (as it reduces uncertainty, hence results in better and more interpretable communication).
6

Sikjær, M., M. S. Wik, S. S. Stensholt, O. Hilberg, and A. Løkke. "Effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: A systematic search and review of the literature." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.793.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Capão, Artur, Braulia Caetano, Paola Resende, Milene Miranda, David Brown, Marilda Siqueira, and Cristiana Garcia. "Effectiveness of 2018 trivalent influenza vaccine on healthcare professionals." In IV International Symposium on Immunobiologicals & VII Seminário Anual Científico e Tecnológico. Instituto de Tecnologia em Imunobiológicos, 2019. http://dx.doi.org/10.35259/isi.sact.2019_32545.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Elbashir, Israa, Aisha Aisha Nasser J. M. Al-Saei, Paul Thornalley, and Naila Rabbani. "Evaluation of antiviral activity of Manuka honey against SARS-CoV-2." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0113.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Background and aims: In 2020 a global pandemic was declared caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). The pandemic is still ongoing and continues to cause considerable mortality and morbidity world-wide and new variants of the virus are emerging. Rapid development and rollout of vaccines for SARS-CoV-2 is in progress to counter the pandemic but has been tempered by the emergence of new SARS-CoV-2 variants, many of which exhibit reduced vaccine effectiveness. To date there is no approved antiviral treatment for coronavirus disease 2019 (COVID-19). Several studies have shown that Manuka honey has virucidal/antiviral effect. Methylglyoxal (MG), a bioactive component in Manuka honey, has antiviral activity in vitro. MG may modify arginine residues in the functional domains of viral spike and nucleocapsid proteins, resulting in loss of charge, protein misfolding and inactivation. The aim of this study was to characterize the antiviral activity of Manuka honey against SARS-CoV-2 in vitro Materials and methods: Wild-type SARS-CoV-2 with titers of multiplicities of infection (MOI) 0.1 and 0.05 were incubated with 2-fold serial dilutions of 250+ Manuka honey (equivalent to 250 to 31 µM) in infection medium (Dulbecco's Modified Eagle Medium + 2% fetal bovine serum + 100 units/ml penicillin + 100 µg/ml streptomycin) for 3 h. Manuka honey treated and untreated control SARS-CoV-2 was incubated with confluent cultures of Vero cells in vitro for 1 h, cultures washed with phosphate-buffered saline and incubated in fresh infection medium at 37°C for 4 - 5 days until 70% of virus control cells displayed cytopathic effect. We also studied the effect of scavenging MG in Manuka Honey with aminoguanidine (AG; 500 µM) on virucidal activity. The antiviral activity of MG was judged by median tissue culture infectious dose (TCID50) assays. Data analysis was by logistic regression. TCID50 (mean ± SD) was deduced by interpolation. Results: Diluted Manuka honey inhibited SARS-CoV-2 replication in Vero cells. SARS-CoV-2 was incubated in diluted Manuka honey in medium at 37°C for 3 h before adding to Vero cells. Manuka honey dilutions down to 125 µM MG equivalents completely inhibited cytopathic effect of SARS-CoV-2 whereas 31.25 µM and 62.5 µM MG equivalents had limited effect. Logistic regression and interpolation of the cytopathic effect indicated that the TCID50 = 72 ± 2 µM MG equivalents for MOI of 0.1. Prior scavenging of MG by addition of AG resulted in virus replication levels equivalent to those seen in the virus control without AG. Conclusion: Manuka honey has antiviral activity against SARS-CoV-2 when incubated with the virus in cell-free media at no greater than ca. 40-fold dilutions of 250+ grade. Anti-viral activity was inhibited by AG, consistent with the anti-viral effect being mediated by MG. Manuka honey dilutions in MG equivalents had similar antiviral effect compared to authentic MG, also consistent with MG content of Manuka honey mediating the antiviral effect. Whilst Manuka honey may inactivate SARS-CoV-2 in cell-free culture medium, its antiviral activity in vivo for other than topical application may be limited because of the rapid metabolism of MG by the glyoxalase system and limited bioavailability of oral MG.
9

Adami, Giovanni, Angelo Fassio, Giovanni Orsolini, Alessandro Giollo, Davide Gatti, and Maurizio Rossini. "OP0230 EFFECTIVENESS OF INFLUENZA VACCINE IN TNF INHIBITORS TREATED PATIENTS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.3088.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Vasileiou, Eleftheria, Colin Simpson, Aziz Sheikh, and Chris Butler. "Seasonal influenza vaccine effectiveness in people with asthma: A systematic review." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa4205.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Vaccines Effectiveness":

1

Ketata, Imen, Rahma Sellami, Marwa Gargouri, Leila Zrelli, Hajer Azzouzi, and Houda Ghorbel. Effectiveness of COVID-19 vaccines in older adults in South Tunisia-Gabes. Peeref, October 2022. http://dx.doi.org/10.54985/peeref.2210p5297898.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Roldan de Jong, Tamara. Rapid Review: Perceptions of COVID-19 Vaccines in South Africa. SSHAP, April 2022. http://dx.doi.org/10.19088/sshap.2021.021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
As of April 19, 2021, South Africa has recorded 1.56 million COVID-19 cases and almost 54,000 deaths - more than any other country on the African continent. The country has begun the national rollout of the Johnson & Johnson (J&J) COVID-19 vaccine, with over 292 thousand doses administered it aims to achieve herd immunity by vaccinating at least 67 percent of its population (around 40 million people) by the end of 2021. The government suspended its initial rollout of the AstraZeneca (AZ) vaccine due to concerns over its effectiveness, particularly against the new B.1.351 variant, which accounts for 90% of the infections in South Africa. The J&J vaccine was put on temporary hold in April due to concerns about rare clotting disorders. Although data show that expected acceptance of COVID-19 vaccines is relatively high, the suspension of two vaccines in South Africa, where fear of infection is decreasing, will likely influence public reactions. Understanding how individuals and population groups perceive and make sense of COVID-19 vaccines is critical to inform the design and implementation of risk communication and community engagement (RCCE) strategies, and guide interventions aiming to promote and sustain acceptance of COVID-19 vaccines, while encouraging compliance with other COVID-19 preventive measures. This review syntheses community perceptions of COVID-19 vaccines in South Africa to inform RCCE strategies and policies and provides examples of successful practice. It draws on multiple secondary data sources: scientific literature, qualitative and quantitative studies, grey literature, and mainstream and social media. The review was supported by consultation with four local expert key informants from different fields. It is part of the Social Science in Humanitarian Action Platform (SSHAP) series on social science considerations relating to COVID-19 vaccines. It was written for SSHAP by Tamara Roldan de Jong and Anthrologica on request of the UNICEF South Africa Country Office. Contributions were made from the RCCE Collective Service East and Southern Africa (ESAR) Region. The brief is the responsibility of SSHAP.
3

Millington, Kerry A. Protecting and Promoting Systems for Essential Health Services During Rollout of COVID-19 Tools. Institute of Development Studies (IDS), May 2021. http://dx.doi.org/10.19088/k4d.2021.084.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
The COVID-19 pandemic has had a tremendous negative impact on economies of most countries around the world. COVID-19 has disrupted the ability of health systems to deliver on essential health services and has also exposed pre-existing vulnerabilities and inequities in public health systems. According to a key informant survey conducted by WHO, over one year into the COVID-19 pandemic, there still exist substantial disruptions to essential health services. This rapid review examines evidence on successful interventions that could enable adaptive approaches to help manage and respond future pandemics and mitigate the risk of collapse of the public health systems. Countries must use the opportunity provided by the deployment of COVID-19 vaccines to strengthen health services and health systems and find long-lasting solutions for similar future challenges. The review notes that there still exist gaps in preparedness and response to the Covid-19 pandemic. New variants of concern threaten the effectiveness of existing COVID-19 vaccines, vaccine hesitancy slowing rollout, including in Africa, and interrupted and limited supply of COVID-19 tools. More funding is required though to scale up adaptive measures which are working, accelerating new approaches and innovations to improve service delivery. This review also highlights briefly the plight of marginalised social groups, people living with disabilities, women and children during the pandemic. According to estimates by Global Fund, Gavi, Global Financing Facility, access to life-saving health interventions for women, children and adolescents in 36 of the world’s poorest countries has dropped by as much as 25% due to COVID-19. Countries must build on the momentum of health innovations during the COVID-19 crisis to build more resilient health systems that can withstand disruptions by future pandemics.
4

Berndt, Ernst, Rachel Glennerster, Michael Kremer, Jean Lee, Ruth Levine, Georg Weizsacker, and Heidi Williams. Advanced Purchase Commitments for a Malaria Vaccine: Estimating Costs and Effectiveness. Cambridge, MA: National Bureau of Economic Research, May 2005. http://dx.doi.org/10.3386/w11288.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Alsan, Marcella, and Sarah Eichmeyer. Experimental Evidence on the Effectiveness of Non-Experts for Improving Vaccine Demand. Cambridge, MA: National Bureau of Economic Research, March 2021. http://dx.doi.org/10.3386/w28593.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Butler, Nadia, and Soha Karam. Key Considerations for Integrating COVID-19 Vaccination Services: Insights from Iraq and Syria for the MENA Region. SSHAP, September 2022. http://dx.doi.org/10.19088/sshap.2022.034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
With the COVID-19 pandemic well into its third year, governments and response partners are recognising that it no longer makes sense for COVID-19 services, including vaccination, to exist in isolation. There is growing recognition of the potential for integration with other services as the way forward for COVID-19 vaccination. This has recently begun to occur in various countries, but until now, there has been little evidence available as to the success of these initiatives. Service delivery integration occurs where “managerial or operational changes to health systems bring together inputs, delivery, management, and organisation of particular service functions in ways that are contextually appropriate and person-centred with the aim of improving coverage, access, quality, acceptability, effectiveness, and cost-effectiveness” (Haldane et al. 2022) This brief draws on evidence from academic and grey literature and consultations with partners working in the COVID-19 response to review current integration efforts (as of August 2022) and explore potentially effective ways to integrate COVID-19 vaccination into other services in the Middle East and North Africa (MENA) region. Recent guidance on integration from WHO has also been cross-referenced where relevant. Iraq is taken as a detailed case study due to the efforts already made there on integration of COVID-19 and routine immunisation (RI) services. Global integration experiences and a brief discussion of integration efforts in Syria are also included. The brief is part of the Social Science in Humanitarian Action Platform (SSHAP) series on social science considerations relating to COVID-19 vaccines and was written for SSHAP by Nadia Butler supported by Soha Karam (Anthrologica). Verbal consultations and reviews of the draft were provided from response partners in Iraq and other locations within the region (IFRC MENARO, Iraq MoH, UNICEF Iraq, UNICEF MENARO, UNICEF Syria, WHO EMRO). The brief was requested by the UNICEF Middle East and North Africa Regional Office (MENARO) and is the responsibility of SSHAP.
7

Russell, Kevin L., Margaret A. Ryan, Anthony Hawksworth, Nikki E. Freed, Marina Irvine, and Luke T. Daum. Effectiveness of the 2003/2004 Influenza Vaccine Among U.S. Military Basic Trainees: A Year of Suboptimal Match Between Vaccine and Circulating Strain. Fort Belvoir, VA: Defense Technical Information Center, June 2004. http://dx.doi.org/10.21236/ada455912.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Paris, Chloe, Julie Spencer, Lauren Castro, and Sara Del Valle. Exploring Impacts to COVID-19 Herd Immunity Thresholds Under Demographic Heterogeneity that Lowers Vaccine Effectiveness. Office of Scientific and Technical Information (OSTI), June 2022. http://dx.doi.org/10.2172/1874147.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Xu, Junjie, Jiaye Liu, Xinquan Lan, Moxin Song, Liangyuan Zhang, and Jiaqi Zhang. Efficacy of the third dose of COVID-19 vaccine: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0114.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Review question / Objective: To investigate the immune response and related clinical outcomes of healthy adults who received coronavirus vaccine booster compared with those who did not receive the vaccine booster. Condition being studied: The COVID-19 pandemic, which has spread since 2019, has created a huge disease and economic burden on the world. A large number of clinical trials have verified the effectiveness of COVID-19 vaccine. Previous studies have found that the serum conversion rate and antibody level of those vaccinated after the first two doses of COVID-19 vaccine continue to decrease, and the efficacy of the vaccine will decrease over time after the first two doses. Therefore, in order to maintain the protective efficacy of the vaccine, The need for a vaccine booster shot to achieve the expected goal of long-term effective prevention of the novel coronavirus has become a focus of discussion around the world.
10

Lamont, Susan J., E. Dan Heller, and Avigdor Cahaner. Prediction of Immunocompetence and Resistance to Disease by Using Molecular Markers of the Major Histocompatibility Complex. United States Department of Agriculture, September 1994. http://dx.doi.org/10.32747/1994.7568780.bard.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
This project utilized two live-animal populations in an integrated research program to identify molecular markers for immune response and disease resistance. The populations each had their foundation from meat-type commercial breeder chicken lines of their respective countries. Investigations effectively used unique availability of resources in each country to study commercial-type environments in Israel and line-crosses with diverse inbred lines in the US. Two bacterial systems were investigated to cover both respiratory and gastrointestinal, and primary and secondary, infections. Individual experimental groups of animals were evaluated for combinations of vaccine antibody levels, response to pathogen challenge, growth parameters, genetic background and molecular markers. The positive association of antibody level with resistance to disease was confirmed. Effectiveness of genetic selection for vaccine antibody response level was demonstrated. Molecular markers, both inside and outside the MHC region, were associated with antibody response and resistance to disease. Markers were shown to have a generalized effect, by association with multiple traits of immune response and disease resistance. The impact of genetic background on marker effect was shown to be important. The overall results demonstrate the effectiveness of selection on vaccine antibody response and the potential of molecular marker-assisted selection to improve efficiency of production of meat-type chickens by reducing genetic susceptibility to disease.

To the bibliography